Search

Your search keyword '"Greg Delgoffe"' showing total 85 results
Start Over "Greg Delgoffe"
85 results on '"Greg Delgoffe"'

53. Immune cells tire out in tumours

Subjects
Tumors -- Health aspects, Mitochondrial DNA -- Health aspects, Environmental issues, Science and technology, Zoology and wildlife conservation
Abstract

After they invade tumours, immune cells gradually lose their ability to produce energy. Greg Delgoffe and his colleagues at the University of Pittsburgh in Pennsylvania studied immune cells called T [...]

Published
2016

63. Novel Immunotherapeutic Approaches to the Treatment of Cancer : Drug Development and Clinical Application

Author

Paul D. Rennert and Paul D. Rennert

Subjects
Cancer--Immunotherapy, Immunotherapy
Abstract

Cancer care is undergoing a radical transformation as novel technologies are directed toward new treatments and personalized medicine. The most dramatic advances in the treatment of cancer have come from therapeutics that augment the immune response to tumors. The immune checkpoint inhibitors are the best-known and most highly advanced examples of Immune Therapeutics targeting tumor cells and include approved antibody drugs directed at the cell surface proteins CTLA4 and PD-1. These are now considered foundational treatments for several solid tumor indications, and that list of indications is growing quickly. More broadly, antibodies have become workhorse molecules across the entire immunotherapy landscape. Antibodies to novel targets modulate the activity of diverse immune cell regulatory proteins. Engineered antibodies can induce tumor cell death or expose tumor cells to poisonous toxins (ADCC and ADC, respectively). Bi-specific antibodies can engage multiple tumor targets simultaneously, or can redirect lymphocytes to attack tumor cells. The antigen-binding domains within antibodies can be spliced onto cell stimulatory domains and transduced into T cells or NK cells, creating remarkable tumor-specific cellular therapeutics (CAR-T, CAR-NK). Beyond antibody-based therapies there are highly diverse and differentiated technology tool kits being applied to immunotherapy. Small molecule drugs are being developed to attack the tumor microenvironment, novel tumor vaccine approaches are showing great promise, patient lymphocytes are being isolated, expanded and reintroduced to patients, gene-editing techniques are becoming widely deployed, and a vast number of new tumor targets, and mutated tumor proteins (neoantigens), are being discovered. The past decade has seen unprecedented success in the treatment of diverse cancers. The authors of this volume have been asked to not only review progress to date, but importantly, to look ahead, and anticipate the evolution of cancer treatment across diverse Immune Therapeutic approaches. Our hypothesis is that the advances we are seeing across the immunotherapy landscape will further evolve and synergize, leading us finally to outright cures for many cancers.

Published
2016

64. New Cancer Research from University of Pittsburgh Outlined (Abstract A020: Neutralizing oxidative damage at telomeres prevents T cell dysfunction and improves adoptive cell therapy)

Subjects
Oncology, Experimental, T cells -- Research, Cancer -- Prevention -- Research, Telomeres -- Research, Business, Health, Health care industry, University of Pittsburgh
Abstract

2023 DEC 19 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Weekly -- New study results on cancer have been published. According to news reporting originating from the [...]

Published
2023

65. KaliVir Immunotherapeutics Establishes Clinical and Scientific Advisory Boards

Subjects
Immunotherapy, B cells, General interest, News, opinion and commentary, University of Pittsburgh. School of Medicine, Memorial Sloan-Kettering Cancer Center
Abstract

PITTSBURGH: KaliVir Immunotherapeutics has issued the following news release: KaliVir Immunotherapeutics, Inc., a biotech company developing cutting-edge, multi-mechanistic oncolytic viral immunotherapy programs, today announced that it has appointed the following [...]

Published
2022

66. KaliVir Immunotherapeutics Establishes Clinical and Scientific Advisory Boards

Subjects
Immunotherapy, B cells, Business, News, opinion and commentary, University of Pittsburgh. School of Medicine, Memorial Sloan-Kettering Cancer Center
Abstract

Experts in oncology, immunotherapy and oncolytic viruses to help guide KaliVir's development of systemically deliverable oncolytic virus immunotherapies PITTSBURGH, Dec. 13, 2022 /PRNewswire/ -- https://c212.net/c/link/?t=0&l=en&o=3734963-1&h=1649061412&u=https%3A%2F%2Fkalivir.com%2F&a=KaliVir+Immunotherapeutics%2C+Inc., a biotech company developing cutting-edge, [...]

Published
2022

67. Novasenta Completes $40 million Series A to Advance Novel Cancer Therapeutics

Subjects
Cancer, General interest, News, opinion and commentary
Abstract

PITTSBURGH: Novasenta has issued the following news release: Novasenta Inc., a startup biotechnology company focused on the discovery and validation of novel targets to develop cancer therapies, today announced the [...]

Published
2022

68. Novasenta Completes $40 million Series A to Advance Novel Cancer Therapeutics

Subjects
Cancer -- Care and treatment, Business, News, opinion and commentary
Abstract

PITTSBURGH, July 29, 2022 /PRNewswire/ -- https://c212.net/c/link/?t=0&l=en&o=3606818-1&h=4149629973&u=https%3A%2F%2Fnovasenta.com%2F&a=Novasenta+Inc., a startup biotechnology company focused on the discovery and validation of novel targets to develop cancer therapies, today announced the completion of $40 [...]

Published
2022

70. TCR2 Therapeutics Inc at JPMorgan Healthcare Conference - Final

Subjects
Business
Abstract

Presentation ERIC JASCHKE;JP MORGAN CHASE & CO, RESEARCH DIVISION;ANALYST: Hi, everyone. My name is Eric Jaschke, with JPMorgan Healthcare. Thanks again for joining this week. I'm pleased to introduce our [...]

Published
2020

71. UPMC Launches Novasenta to Develop Targeted Immunotherapy Drugs for Cancer

Subjects
Drug discovery, Immunotherapy, Cancer -- Drug therapy, Business, News, opinion and commentary
Abstract

PITTSBURGH, Aug. 24, 2021 /PRNewswire/ -- As part of its commitment to investing in translational science that significantly improves the lives of patients, UPMC has launched Novasenta, a drug discovery [...]

Published
2021

72. Pieris Pharmaceuticals, Inc. Special Call - Final

Subjects
Atezolizumab, Medical schools, Butterflies, Business, University of Pittsburgh
Abstract

Presentation STEPHEN S. YODER, CEO, PRESIDENT & DIRECTOR, PIERIS PHARMACEUTICALS, INC.: (technical difficulty) Joining me from the Pieris side upfront are Ingmar Bruns, MD, PhD, our Head of Clinical Development; [...]

Published
2019

73. CANCER TRICKS IMMUNE CELLS, IMMUNOTHERAPY CAN TAKE ADVANTAGE

Subjects
Immunotherapy, Cancer -- Care and treatment -- Drug therapy, News, opinion and commentary, University of Pittsburgh. School of Medicine
Abstract

PITTSBURGH, PA -- The following information was released by the University of Pittsburgh: A paper published today in Nature shows how chemicals in the areas surrounding tumors--known as the tumor [...]

Published
2021

75. Century Therapeutics Announces Formation of Scientific Advisory Board

Subjects
B cells, Stem cells, Stem cell transplantation, Stem cell research, Cancer treatment, Scientists, Cancer, Cells (Biology), Business, international, Law
Abstract

Century Therapeutics, developer of induced pluripotent stem cell (iPSC)-derived allogeneic cell therapies for cancer, today announced the formation of its Scientific Advisory Board (SAB) to include several renowned experts in [...]

Published
2020

76. Century Therapeutics Announces Formation of Scientific Advisory Board

Subjects
B cells, Stem cells, Stem cell transplantation, Stem cell research, Cancer treatment, Scientists, Cancer, Cells (Biology), General interest, News, opinion and commentary
Abstract

PHILADELPHIA: Century Therapeutics has issued the following press release: -Century Therapeutics, developer of induced pluripotent stem cell (iPSC)-derived allogeneic cell therapies for cancer, today announced the formation of its Scientific [...]

Published
2020

77. Century Therapeutics Announces Formation of Scientific Advisory Board

Subjects
B cells, Stem cells, Stem cell transplantation, Stem cell research, Cancer treatment, Scientists, Cancer, Cells (Biology), Business, Business, international
Abstract

PHILADELPHIA -- Century Therapeutics, developer of induced pluripotent stem cell (iPSC)-derived allogeneic cell therapies for cancer, today announced the formation of its Scientific Advisory Board (SAB) to include several renowned [...]

Published
2020

79. Findings from National Cancer Institute (NCI) Provide New Insights into Solid Cancer (Challenges and next steps in the advancement of immunotherapy: summary of the 2018 and 2020 National Cancer Institute workshops on cell-based immunotherapy ...)

Subjects
United States. National Cancer Institute -- Conferences, meetings and seminars -- Reports, Immunotherapy -- Conferences, meetings and seminars -- Reports, Cancer -- Conferences, meetings and seminars -- Reports, Workshops (Educational programs) -- Conferences, meetings and seminars -- Reports, Business, Health, Health care industry
Abstract

2021 AUG 3 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Weekly -- Investigators publish new report on solid cancer. According to news reporting originating from the National [...]

Published
2021

81. Melanoma Research Alliance Announces $11 Million for 26 Grant Awards to Advance Melanoma Research

Subjects
Cancer treatment -- Health aspects, Cancer genetics -- Health aspects, Research funding -- Health aspects, Anopheles, Editors, Biotechnology industry, Health, Science and technology
Abstract

2020 MAY 11 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Gene Therapy Week -- With the world's attention focused on the response to COVID-19, the Melanoma Research [...]

Published
2020

82. The Sidney Kimmel Foundation For Cancer Research Announces 2015 Grant Recipients

Subjects
Research scientists, Cancer, Cancer research, Research funding, Business, general
Abstract

(PRWEB) May 21, 2015 The Sidney Kimmel Foundation for Cancer Research has selected the 2015 recipients for the Kimmel Scholar Program. Fifteen research scientists and medical doctors from across the [...]

Published
2015

85. Mechanism offers promising new approach for harnessing the immune system to fight cancer

Subjects
T cells, Immune system, Immunotherapy, Cancer -- Drug therapy, Vaccines, Melanoma -- Drug therapy, Pharmaceuticals and cosmetics industries, Health, Science and technology
Abstract

By a News Reporter-Staff News Editor at Cancer Vaccine Week -- St. Jude Children's Research Hospital scientists have discovered a way to target the immune system to shrink or eliminate [...]

Published
2013

Catalog

Books, media, physical & digital resources
See catalog results